ANTITUMOR ACTIVITY OF A NEW CAMPTOTHECIN DERIVATIVE, SN-22, AGAINST VARIOUS MURINE TUMORS

TAKEHIKO KUNIMOTO; KAZUO NITTA; TOMIKO TANAKA; NOBUAKI UEHARA; HIROYASU BABA; MIEKO TAKEUCHI; TERUO YOKOKURA; SEIGO SAWADA; TADASHI MIYASAKA; MASAHIKO MUTAI

doi:10.1248/bpb1978.10.148

TAKEHIKO KUNIMOTO, KAZUO NITTA, TOMIKO TANAKA, NOBUAKI UEHARA, HIROYASU BABA, MIEKO TAKEUCHI, TERUO YOKOKURA, SEIGO SAWADA, TADASHI MIYASAKA, MASAHIKO MUTAI

Author information

TAKEHIKO KUNIMOTO
KAZUO NITTA
TOMIKO TANAKA
NOBUAKI UEHARA
HIROYASU BABA
MIEKO TAKEUCHI
TERUO YOKOKURA
SEIGO SAWADA
TADASHI MIYASAKA
MASAHIKO MUTAI
Author's Organization：
Chemotherapy Division National Cancer Center Research Institute
Pharmacology Division National Cancer Center Research Institute:Yakult Central Institute:Showa University School of Pharmaceutical Sciences National Cancer Center Research Institute
Chemotherapy Division National Cancer Center Research Institute
Pharmacology Division National Cancer Center Research Institute:Yakult Central Institute:Showa University School of Pharmaceutical Sciences National Cancer Center Research Institute
Chemotherapy Division National Cancer Center Research Institute
Pharmacology Division National Cancer Center Research Institute:Yakult Central Institute:Showa University School of Pharmaceutical Sciences National Cancer Center Research Institute
Chemotherapy Division National Cancer Center Research Institute
Pharmacology Division National Cancer Center Research Institute:Yakult Central Institute:Showa University School of Pharmaceutical Sciences National Cancer Center Research Institute
Chemotherapy Division National Cancer Center Research Institute
Pharmacology Division National Cancer Center Research Institute:Yakult Central Institute:Showa University School of Pharmaceutical Sciences National Cancer Center Research Institute
Chemotherapy Division National Cancer Center Research Institute
Pharmacology Division National Cancer Center Research Institute:Yakult Central Institute:Showa University School of Pharmaceutical Sciences National Cancer Center Research Institute
Chemotherapy Division National Cancer Center Research Institute
Pharmacology Division National Cancer Center Research Institute:Yakult Central Institute:Showa University School of Pharmaceutical Sciences National Cancer Center Research Institute
Chemotherapy Division National Cancer Center Research Institute
Pharmacology Division National Cancer Center Research Institute:Yakult Central Institute:Showa University School of Pharmaceutical Sciences National Cancer Center Research Institute
Chemotherapy Division National Cancer Center Research Institute
Pharmacology Division National Cancer Center Research Institute:Yakult Central Institute:Showa University School of Pharmaceutical Sciences National Cancer Center Research Institute
Chemotherapy Division National Cancer Center Research Institute
Pharmacology Division National Cancer Center Research Institute:Yakult Central Institute:Showa University School of Pharmaceutical Sciences National Cancer Center Research Institute

Keywords: murine tumor

JOURNAL FREE ACCESS

1987 Volume 10 Issue 3 Pages 148-151

DOI https://doi.org/10.1248/bpb1978.10.148

Details

Abstract

The antitumor activity of a new camptothecin derivative, SN-22, was evaluated by using various murine tumors. SN-22 showed strong activity against the ascites tumors Ehrlich carcinoma, MM46, CCM, L1210, L5178Y, P388, Meth A, and B16 melanoma. In particular, the maximum increase in life span values for Ehrlich, MM46 and CCM were as high as 253-606% and many mice were cured of these tumors. The effect of SN-22 against solid tumors was also determined. The inhibition ratios were higher than 70% for MM46 and L5178Y. The LD₅₀ of SN-22 in ICR mice was about 1.5 times that of the parent camptothecin.

Corresponding author

Register with J-STAGE for free!